UA102677C2 - Хіноксалінвмісні сполуки як інгібітори вірусу гепатиту с - Google Patents

Хіноксалінвмісні сполуки як інгібітори вірусу гепатиту с

Info

Publication number
UA102677C2
UA102677C2 UAA201007220A UAA201007220A UA102677C2 UA 102677 C2 UA102677 C2 UA 102677C2 UA A201007220 A UAA201007220 A UA A201007220A UA A201007220 A UAA201007220 A UA A201007220A UA 102677 C2 UA102677 C2 UA 102677C2
Authority
UA
Ukraine
Prior art keywords
present
hepatitis
virus
compounds
quinoxaline
Prior art date
Application number
UAA201007220A
Other languages
English (en)
Russian (ru)
Inventor
Юнхуа Гай
Ят Сунь Ор
Чже Ван
Original Assignee
Енанта Фармасьютікалз, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Енанта Фармасьютікалз, Інк. filed Critical Енанта Фармасьютікалз, Інк.
Publication of UA102677C2 publication Critical patent/UA102677C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Даний винахід розкриває сполуки формул І і II або їх фармацевтично прийнятні солі, естери або проліки, які інгібують активність серинпротеази, зокрема активність протеази NS3-NS4A вірусу гепатиту С (HCV). Внаслідок цього, сполуки за даним винаходом порушують життєвий цикл вірусу гепатиту С і можуть також застосовуватися як противірусні засоби. Крім того, даний винахід стосується фармацевтичних композицій, що включають згадані вище сполуки, для введення суб'єкту, що страждає від HCV-інфекції. Винахід також стосується способів лікування HCV-інфекції у суб'єкта шляхом введення фармацевтичної композиції, що включає сполуки за даним винаходом. EMBED ISISServer , (I) EMBED ISISServer (II).
UAA201007220A 2007-11-14 2008-11-14 Хіноксалінвмісні сполуки як інгібітори вірусу гепатиту с UA102677C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98795807P 2007-11-14 2007-11-14
US2545808P 2008-02-01 2008-02-01
PCT/US2008/083541 WO2009064975A1 (en) 2007-11-14 2008-11-14 Quinoxaline-containing compounds as hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
UA102677C2 true UA102677C2 (uk) 2013-08-12

Family

ID=40639146

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201007220A UA102677C2 (uk) 2007-11-14 2008-11-14 Хіноксалінвмісні сполуки як інгібітори вірусу гепатиту с

Country Status (26)

Country Link
US (2) US8324155B2 (uk)
EP (1) EP2219453B1 (uk)
JP (1) JP5479354B2 (uk)
KR (1) KR20100098527A (uk)
CN (1) CN101909446A (uk)
AR (1) AR069464A1 (uk)
AU (1) AU2008322537A1 (uk)
BR (1) BRPI0820085A2 (uk)
CA (1) CA2705807A1 (uk)
CL (1) CL2008003384A1 (uk)
CO (1) CO6280441A2 (uk)
CR (1) CR11499A (uk)
DO (1) DOP2010000143A (uk)
EC (1) ECSP10010254A (uk)
ES (1) ES2476257T3 (uk)
HK (1) HK1146693A1 (uk)
IL (1) IL205611A0 (uk)
MX (1) MX2010005262A (uk)
MY (1) MY155851A (uk)
PE (2) PE20140189A1 (uk)
RU (1) RU2493160C2 (uk)
TW (1) TWI431011B (uk)
UA (1) UA102677C2 (uk)
UY (1) UY31470A1 (uk)
WO (1) WO2009064975A1 (uk)
ZA (1) ZA201003363B (uk)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606195C (en) 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
CA2615896C (en) 2005-08-01 2012-11-13 Merck & Co., Inc. Macrocyclic peptides as hcv ns3 protease inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
WO2008051477A2 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
AU2007309488B2 (en) 2006-10-24 2012-10-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2008057208A2 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
MY164469A (en) 2006-10-27 2017-12-15 Msd Italia Srl Hcv ns3 protease inhibitors
US8101595B2 (en) 2006-12-20 2012-01-24 Istituto di Ricerche di Biologia Molecolare P. Angletti SpA Antiviral indoles
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2693537C (en) 2007-07-17 2013-06-25 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis c infections
JP5433573B2 (ja) 2007-07-19 2014-03-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ 抗ウイルス剤としての大環状化合物
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8030307B2 (en) * 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
US8222203B2 (en) 2007-12-14 2012-07-17 Enanta Pharmaceuticals, Inc. Macrocyclic oximyl hepatitis C serine protease inhibitors
US8283309B2 (en) 2007-12-20 2012-10-09 Enanta Pharmaceuticals, Inc. Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
JP2011510927A (ja) 2008-01-24 2011-04-07 エナンタ ファーマシューティカルズ インコーポレイテッド Ｈｃｖセリンプロテアーゼ阻害剤としての二フッ素化トリペプチド
CA2720850A1 (en) 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US8211891B2 (en) * 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
CA2731177C (en) 2008-07-22 2013-10-29 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
JP5639155B2 (ja) * 2009-05-13 2014-12-10 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルスインヒビターとしての大環状化合物
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
WO2011049908A2 (en) * 2009-10-19 2011-04-28 Enanta Pharmaceuticals, Inc. Bismacrokyclic compounds as hepatitis c virus inhibitors
JP2013518060A (ja) 2010-01-25 2013-05-20 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス阻害剤
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
KR101781789B1 (ko) 2010-01-27 2017-09-26 에이비 파르마 리미티드. C형 간염 바이러스 억제제로 사용되는 다환 헤테로사이클릭 화합물
WO2011127350A1 (en) * 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
SG188618A1 (en) 2010-09-21 2013-04-30 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2857705A1 (en) 2011-06-16 2012-12-20 AB Pharma Ltd. Macrocyclic heterocyclic compounds for inhibiting hepatitis c virus and preparation and use thereof
PT2861604T (pt) 2012-06-08 2017-05-05 Gilead Sciences Inc Inibidores macrocíclicos de vírus flaviridae
AR091279A1 (es) * 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
CA2875718A1 (en) 2012-06-08 2013-12-12 Selcia Limited Macrocyclic inhibitors of flaviviridae viruses
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
DK2909205T3 (en) 2012-10-19 2017-03-06 Bristol Myers Squibb Co 9-METHYL-SUBSTITUTED HEXADECAHYDROCYCLOPROPA (E) PYRROL (1,2-A) (1,4) DIAZOCYCLOPENTADECINYLCARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR TREATMENT
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9617310B2 (en) 2013-03-15 2017-04-11 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
JP6568541B2 (ja) * 2013-12-23 2019-08-28 ギリアド ファーマセット エルエルシー 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態
US9440991B2 (en) * 2013-12-23 2016-09-13 Gilead Sciences, Inc. Synthesis of an antiviral compound
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CN107266529A (zh) * 2016-04-08 2017-10-20 上海长森药业有限公司 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途
CN107074876B (zh) * 2016-04-08 2019-12-20 上海长森药业有限公司 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途
RU2650610C1 (ru) * 2017-02-28 2018-04-16 Васильевич Иващенко Александр Противовирусная композиция и способ ее применения
CN107987083A (zh) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4748911B2 (ja) 2000-04-05 2011-08-17 シェーリング コーポレイション Ｎ−環状ｐ２部分を含むｃ型肝炎ウイルスの大環状ｎｓ３‐セリンプロテアーゼ阻害剤
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
CA2606195C (en) 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
EP2103623A3 (en) * 2005-07-25 2009-12-16 Intermune, Inc. Novel macrocyclic inhibitors of Hepatitis C virus replication
CA2615896C (en) * 2005-08-01 2012-11-13 Merck & Co., Inc. Macrocyclic peptides as hcv ns3 protease inhibitors
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) * 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
TWI454264B (zh) * 2006-06-26 2014-10-01 Enanta Pharm Inc 喹啉基巨環ｃ型肝炎病毒絲胺酸蛋白酶抑制劑
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7582605B2 (en) * 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
MY164469A (en) * 2006-10-27 2017-12-15 Msd Italia Srl Hcv ns3 protease inhibitors
WO2008134397A1 (en) * 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
US20080267917A1 (en) * 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US8377872B2 (en) * 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
JP5433573B2 (ja) 2007-07-19 2014-03-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ 抗ウイルス剤としての大環状化合物
US8383583B2 (en) * 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
MX2010005261A (es) * 2007-11-14 2010-10-15 Enanta Pharm Inc Inhibidores macrocíclicos de proteasa de serina de hepatitis c de tetrazolilo.
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
EP2224942A4 (en) * 2007-12-05 2012-01-25 Enanta Pharm Inc FLUORATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS
CA2708042A1 (en) * 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Quinoxalinyl derivatives
US8273709B2 (en) * 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
US8222203B2 (en) * 2007-12-14 2012-07-17 Enanta Pharmaceuticals, Inc. Macrocyclic oximyl hepatitis C serine protease inhibitors
US8283309B2 (en) * 2007-12-20 2012-10-09 Enanta Pharmaceuticals, Inc. Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors

Also Published As

Publication number Publication date
TW200938550A (en) 2009-09-16
BRPI0820085A2 (pt) 2019-09-24
TWI431011B (zh) 2014-03-21
HK1146693A1 (en) 2011-07-08
JP5479354B2 (ja) 2014-04-23
DOP2010000143A (es) 2010-07-31
CA2705807A1 (en) 2009-05-22
EP2219453A1 (en) 2010-08-25
PE20091212A1 (es) 2009-09-13
CR11499A (es) 2010-10-25
RU2010123928A (ru) 2011-12-20
EP2219453B1 (en) 2014-04-09
CO6280441A2 (es) 2011-05-20
ECSP10010254A (es) 2010-07-30
PE20140189A1 (es) 2014-03-12
EP2219453A4 (en) 2011-01-19
ES2476257T3 (es) 2014-07-14
ZA201003363B (en) 2011-04-28
US20130144036A1 (en) 2013-06-06
CN101909446A (zh) 2010-12-08
AU2008322537A1 (en) 2009-05-22
US20100003214A1 (en) 2010-01-07
MX2010005262A (es) 2010-08-10
RU2493160C2 (ru) 2013-09-20
JP2011505339A (ja) 2011-02-24
US8951998B2 (en) 2015-02-10
US8324155B2 (en) 2012-12-04
AR069464A1 (es) 2010-01-27
WO2009064975A1 (en) 2009-05-22
KR20100098527A (ko) 2010-09-07
MY155851A (en) 2015-12-15
IL205611A0 (en) 2010-11-30
UY31470A1 (es) 2009-07-17
CL2008003384A1 (es) 2009-12-11

Similar Documents

Publication Publication Date Title
UA102677C2 (uk) Хіноксалінвмісні сполуки як інгібітори вірусу гепатиту с
MX2010006209A (es) Derivados de quinoxalinilo.
MX2010010276A (es) Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
MX2010005261A (es) Inhibidores macrocíclicos de proteasa de serina de hepatitis c de tetrazolilo.
WO2008022006A3 (en) Arylalkoxyl hepatitis c virus protease inhibitors
WO2008021956A3 (en) Acylaminoheteroaryl hepatitis c virus protease inhibitors
MX2010006518A (es) Inhibidores de serina proteasa de hepatitis c de oximil macrociclica.
WO2009076166A3 (en) Oximyl hcv serine protease inhibitors
WO2007143694A3 (en) Macrocyclic oximyl hepatitis c protease inhibitors
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
MX2019013037A (es) Prolina macrociclica derivada de inhibidores de serina proteasa de vhc.
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
MX2011012155A (es) Compuestos macrociclicos como inhibidores del virus de hepatitis c.
WO2008021960A3 (en) Triazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008019289A3 (en) Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008021733A3 (en) Tetrazolyl acyclic hepatitis c serine protease inhibitors
WO2008019303A3 (en) Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
MY160130A (en) Hepatitis c virus inhibitors
WO2008002924A3 (en) Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2011049908A3 (en) Bismacrokyclic compounds as hepatitis c virus inhibitors
TN2012000358A1 (en) Hepatitis c virus inhibitors
MX2010008109A (es) Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).
EP2555622A4 (en) HEPATITIS C-VIRUS HEMMER